当前位置：药药网 / 药品 / 美国NDC复合药物数据库文件(本栏目更新到2026-3-31)
药品名称： 商品名称： 药品NDC： 报告期内： -格式:2020-5-3
NDC包装id： 市场分类： 活性成分： 持证企业：
 美国NDC复合药物数据库文件4843条(本栏目更新到2026-3-31)
药品名称(分析)
商品名
药品NDC
专利人(分析)
报告期内
活性成分
市场分类
规格(分析)
NDC包装id
Diclofenac Sodium
HUMAN COMPOUNDED DRUG
71300-6632
Nubratori Inc.
2024-2
DICLOFENAC SODIUM
OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
16 mg/1 g
71300-6632-1
S-TT200
HUMAN COMPOUNDED DRUG
79559-6200
F. H. Investments. Inc. DBA Asteria Health
2024-2
TRIAMCINOLONE ACETONIDE; TESTOSTERONE
OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
.04 mg/200 mg; 200 mg/200 mg
79559-6200-1
S-TA104
HUMAN COMPOUNDED DRUG
79559-4104
F. H. Investments. Inc. DBA Asteria Health
2024-2
TESTOSTERONE; ANASTROZOLE
OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
100 mg/104 mg; 4 mg/104 mg
79559-4104-1
S-TA079
HUMAN COMPOUNDED DRUG
79559-4079
F. H. Investments. Inc. DBA Asteria Health
2024-2
TESTOSTERONE; ANASTROZOLE
OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
75 mg/79 mg; 4 mg/79 mg
79559-4079-1
S-E022
HUMAN COMPOUNDED DRUG
79559-3022
F. H. Investments. Inc. DBA Asteria Health
2024-2
ESTRADIOL
OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
22 mg/22 mg
79559-3022-1
011220 NIACINAMIDE 2% / SPIRONOLACTONE 5% / TRETINOIN 0.05% Gel
HUMAN COMPOUNDED DRUG
72934-1315
SKNV
2024-2
TRETINOIN; NIACINAMIDE; SPIRONOLACTONE
OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
.05 g/100 mL; 2 g/100 mL; 5 g/100 mL
72934-1315-2
011522 BENZOYL PEROXIDE 5% / CLINDAMYCIN 1% / NIACINAMIDE 2% / TRETINOIN 0.05% Gel
HUMAN COMPOUNDED DRUG
72934-1331
SKNV
2024-2
BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE; NIACINAMIDE; TRETINOIN
OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
5 g/100 mL; 1 g/100 mL; 2 g/100 mL; .05 g/100 mL
72934-1331-2
031100 MINOXIDIL 7% / NIACINAMIDE 4%
HUMAN COMPOUNDED DRUG
72934-4356
SKNV
2024-2
MINOXIDIL; NIACINAMIDE
OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
7 g/100 mL; 4 g/100 mL
72934-4356-8
011191 CLINDAMYCIN 1% / NIACINAMIDE 4% / TRETINOIN 0.025%
HUMAN COMPOUNDED DRUG
72934-4312
SKNV
2024-2
CLINDAMYCIN PHOSPHATE; TRETINOIN; NIACINAMIDE
OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
1 g/100 mL; .025 g/100 mL; 4 g/100 mL
72934-4312-3
011553 DAPSONE 6% / NIACINAMIDE 2% / SPIRONOLACTONE 5% Cream
HUMAN COMPOUNDED DRUG
72934-2322
SKNV
2024-2
DAPSONE; NIACINAMIDE; SPIRONOLACTONE
OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
6 g/100 mL; 2 g/100 mL; 5 g/100 mL
72934-2322-2
011520 BENZOYL PEROXIDE 2.5% / CLINDAMYCIN 1% / NIACINAMIDE 2% / TRETINOIN 0.025% Gel
HUMAN COMPOUNDED DRUG
72934-1329
SKNV
2024-2
BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE; NIACINAMIDE; TRETINOIN
OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
2.5 g/100 mL; 1 g/100 mL; 2 g/100 mL; .025 g/100 mL
72934-1329-2
011032 NIACINAMIDE 4% / TRETINOIN 0.025%
HUMAN COMPOUNDED DRUG
72934-2307
SKNV
2024-1
NIACINAMIDE; TRETINOIN
OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
4 g/100 mL; .025 g/100 mL
72934-2307-2
011034 NIACINAMIDE 4% / TRETINOIN 0.05%
HUMAN COMPOUNDED DRUG
72934-2308
SKNV
2024-1
NIACINAMIDE; TRETINOIN
OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
4 g/100 mL; .05 g/100 mL
72934-2308-2
021020 IMIQUIMOD 5% / LEVOCETIRIZINE DIHYDROCHLORIDE 1% / TRETINOIN 0.05% Gel
HUMAN COMPOUNDED DRUG
72934-1339
SKNV
2024-1
TRETINOIN; LEVOCETIRIZINE DIHYDROCHLORIDE; IMIQUIMOD
OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
.05 g/100 mL; 1 g/100 mL; 5 g/100 mL
72934-1339-2
011528 BENZOYL PEROXIDE 5% / CLINDAMYCIN 1% / NIACINAMIDE 2% / SPIRONOLACTONE 2% / TRETINOIN 0.05% Gel
HUMAN COMPOUNDED DRUG
72934-1334
SKNV
2024-1
SPIRONOLACTONE; BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE; NIACINAMIDE; TRETINOIN
OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
2 g/100 mL; 5 g/100 mL; 1 g/100 mL; 2 g/100 mL; .05 g/100 mL
72934-1334-2
Ketamine HCl
HUMAN COMPOUNDED DRUG
73013-2004
OurPharma LLC
2023-2
KETAMINE HYDROCHLORIDE
OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
.3 mg/1 mL
73013-2004-1
fentanyl citrate, ropivacaine hydrochloride
HUMAN COMPOUNDED DRUG
73013-1052
OurPharma LLC
2023-2
FENTANYL CITRATE; ROPIVACAINE HYDROCHLORIDE
OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
2 ug/1 mL; 2 mg/1 mL
73013-1052-1
Bupivacaine HCl
HUMAN COMPOUNDED DRUG
73013-4006
OurPharma LLC
2023-2
BUPIVACAINE HYDROCHLORIDE
OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
2 mg/1 mL
73013-4006-2
fentanyl citrate, bupivacaine hydrochloride
HUMAN COMPOUNDED DRUG
73013-1014
OurPharma LLC
2023-2
FENTANYL CITRATE; BUPIVACAINE HYDROCHLORIDE
OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
2 ug/1 mL; 1.25 mg/1 mL
73013-1014-1
fentanyl citrate, bupivacaine hydrochloride
HUMAN COMPOUNDED DRUG
73013-1027
OurPharma LLC
2023-2
BUPIVACAINE HYDROCHLORIDE; FENTANYL CITRATE
OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
.625 mg/1 mL; 2 ug/1 mL
73013-1027-1
网站地图 - 网站开发 - 网站简介 - 会员服务 - 法律声明 - 联系我们 - 药品招商频道 - 药品信息排行 - 2018年版国家基本药物目录 - 意见反馈
免责声明：以上所展示的信息由企业自行提供，内容的真实性、准确性和合法性由发布企业负责，医药网对此不承担任何责任。
相关链接：医药研究数据| 医药资料| SDA药品评审中心| 中医网| 中药处方系统| 爱视立眼贴
专业提供药品信息、药品招商、药品代理、保健品招商、医药原料采购供应的中国药品信息网站平台
版权所有 © 2003-2028 盗冒必究　　客服热线：0575-83552251 / 13754370441  QQ客服：药品信息客服
浙ICP备16010490号-2 增值电信业务经营许可证：浙B2-20220931　互联网药品信息服务资格证书编号：(浙)-经营性2023-0215　浙公网安备:330683240604819103159
　医药代理商群１：药药网药品采购交流医药代理商群２：药药网药品采购交流2医药代理商群３：药药网药品采购交流3